Breathing and Attention Training for Chronic Low Back Pain

Sponsor
University of Florida (Other)
Overall Status
Recruiting
CT.gov ID
NCT04740710
Collaborator
(none)
30
1
2
20
1.5

Study Details

Study Description

Brief Summary

The purpose of this research study is to see if breathing and attention training (BAT) treatments improve pain symptoms and well-being in people who have chronic low back pain (cLBP). For this breathing intervention, you will be randomly assigned to either standard or focused BAT. The standard BAT includes instructions on deep breathing and relaxation. The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help you focus and alter your breathing patterns.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Breathing and Attention Training
Phase 1/Phase 2

Detailed Description

The primary objective of the proposed pilot randomized controlled trial (RCT) is to examine the safety, feasibility, and acceptability of a 5-day breathing and attention training (BAT) in a sample of 30 adults with cLBP. The secondary objective is to explore preliminary clinical efficacy and potential mechanisms of the breathing interventions (focused-BAT and standard-BAT), by examining changes in clinical pain outcomes and potential pain-related psychological, physiological, and behavioral mediating variables. Both interventions will be delivered via an audio recording in order to standardize the interventions across participants and to enhance treatment fidelity. Results from this study will inform the successful design and implementation of a larger RCT and provide preliminary evidence regarding the potential efficacy of this breathing intervention for people with cLBP.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Breathing and Attention Training for Chronic Low Back Pain
Actual Study Start Date :
Jul 18, 2021
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Mar 19, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Breathing and Attention Training

The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.

Behavioral: Breathing and Attention Training
A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.

Experimental: Focused Breathing and Attention Training

The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help focus and alter breathing patterns. Participants will practice focused BAT once a day for 15 minutes for 5 days in a row.

Behavioral: Breathing and Attention Training
A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.

Outcome Measures

Primary Outcome Measures

  1. Treatment Satisfaction Questionnaire [3-months]

    Treatment acceptability and participant satisfaction will be measured with several items rated on a 10-point scale where higher scores represent greater treatment acceptability and satisfaction.

  2. Incidence of Adverse Events [Through study completion, up to 3-months]

    Number of serious adverse events

Secondary Outcome Measures

  1. Change in Pain Intensity [Baseline, Day 1, Day 2, Day 3, Day 4, Day 5]

    Numerical rating scale (1- "No pain", 10- "Worst pain imaginable") of current pain intensity measured before and after each intervention session.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chronic low back pain consistent with recommendations of the NIH task force on cLBP (i.e., participants with cLBP of at least moderate impact that has persisted on more days than not over the past 3 months)

  • Age 18-65

Exclusion Criteria:
  • Systemic rheumatic disease/condition (e.g. rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia).

  • Asthma, breathing problems, or a respiratory disorder (e.g., chronic obstructive pulmonary disease).

  • Daily use of opioids. We will exclude patients using opioids daily as both continued use and temporary withdrawal from these medications this could affect pain perception and response to interventions. Other medications being used will be recorded and controlled in statistical analyses as needed.

  • Uncontrolled hypertension (i.e. SBP/DBP of > 150/95), orthostatic hypotension, cardiovascular or peripheral arterial disease. These exclusions are in place primarily for safety reasons, however, uncontrolled hypertension can also affect pain perception, which is another reason for excluding these individuals.

  • Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy, vasovagal syncope) or evidence of previous brain injury, including stroke and traumatic brain injury.

  • Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation.

  • Current substance use disorder or history of hospitalization for treatment of substance use disorder.

  • Pregnant

  • Any significant comorbidities that, in the opinion of the investigators, could interfere with the study or lead to deleterious effects for the patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Florida Gainesville Florida United States 32610

Sponsors and Collaborators

  • University of Florida

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Steven Pratscher, Ph.D., University of Florida
ClinicalTrials.gov Identifier:
NCT04740710
Other Study ID Numbers:
  • Breathe for Pain
  • OCR39823
  • IRB202002612
First Posted:
Feb 5, 2021
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Steven Pratscher, Ph.D., University of Florida
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022